Welcome To SteroidScience.org

A comprehensive resource of relevant human studies of anabolic steroids for bodybuilders, athletes and students.
Showing posts with label Methyltestosterone. Show all posts
Showing posts with label Methyltestosterone. Show all posts

Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids.

. Wednesday, 13 August 2008
0 comments

S Afr Med J. 1976 Jul 24;50(32):1233-7.

Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment
with androgenic steroids.

Kew MC, Van Coller B, Prowse CM, Skikne B, Wolfsdorf JI, Isdale J, Krawitz S,
Altman H, Levin SE, Bothwell TH.

Three patients are reported in whom treatment of Fanconi's anaemia with
androgenic steroids was complicated by the development of either primary
hepatocellular cancer (PHC) or peliosis hepatis. The first, a White woman aged 34
years, was found to have PHC after receiving first methyltestosterone and then
oxymetholone for a total period of 7 years. She died 4 months after the diagnosis
was made. The other 2 patients were White children who presented with peliosis
hepatis after receiving methyltestosterone and oxymetholone for 8 years and
oxymetholone for 5 years, respectively. Both died from their primary diseases
shortly after oxymetholone treatment was discontinued. Possible pathogenic
mechanisms involved in the development of these serious complications are
discussed and the therapeutic dilemma raised by their occurrence is emphasised.

Oxandrolone treatment of childhood hereditary angioedema.

. Friday, 11 July 2008
0 comments

Ann Allergy Asthma Immunol. 2004 Mar;92(3):377-8.

Oxandrolone treatment of childhood hereditary angioedema.

Church JA.

Division of Clinical Immunology and Allergy, Department of Pediatrics, Childrens
Hospital Los Angeles and Keck of School of Medicine, The University of Southern
California, Los Angeles, California 90027, USA. jchurch@chla.usc.edu

BACKGROUND: The virilizing effects of danazol, stanozolol, and methyltestosterone
significantly restrict the usefulness of these agents in the treatment of
children with hereditary angioedema (HAE). Oxandrolone is a synthetic anabolic
steroid with limited virilizing effects that has been used in a variety of
pediatric conditions and has an acceptable safety profile.

OBJECTIVE: To report
the effective use of oxandrolone in a 6-year-old boy with recurrent,
life-threatening episodes of angioedema.

METHODS: Oxandrolone was administered at
a dose of 0.1 mg/kg per day. Symptoms and laboratory findings were evaluated by
parental report and laboratory analysis of serum C1 esterase inhibitor and C4
levels, respectively.

RESULTS: Oxandrolone therapy resulted in a marked reduction
in clinical episodes and normalization of serum complement levels; cessation of
oxandrolone therapy resulted in recurrence of symptoms and decreased complement
levels. However, early signs of virilization were noted.

CONCLUSIONS: Oxandrolone
treatment was associated with significant clinical and laboratory evidence of a
therapeutic effect in a prepuberal boy with HAE. It is imperative to treat HAE
with the lowest dose of oxandrolone that controls life-threatening episodes of
angioedema

Species, sex and inter-individual differences in DNA repair induced by nine sex steroids in primary cultures of rat and human hepatocytes.

.
0 comments

Mutat Res. 2003 Apr 20;536(1-2):69-78.

Species, sex and inter-individual differences in DNA repair induced by nine sex
steroids in primary cultures of rat and human hepatocytes.

Martelli A, Mattioli F, Angiola M, Reimann R, Brambilla G.

Department of Internal Medicine, Division of Clinical Pharmacology and
Toxicology, University of Genoa, Viale Benedetto XV 2, I-16132, Genoa, Italy.

Sex steroids, due to the generally negative responses observed in routinely
employed standard genotoxicity assays, are considered epigenetic carcinogens.
Some doubts on this conviction are raised by the results of recent studies
providing evidence that cyproterone acetate and two structural analogues,
chlormadinone acetate and megestrol acetate, are genotoxic in female rats but
only for the liver, and in primary human hepatocytes from donors of both genders.
The experimental evidence suggests that the metabolic activation of these
molecules to reactive species and the consequent formation of DNA adducts occur
only in the intact hepatocyte. Since the possibility that other sex steroids
cause a liver-specific genotoxic effect cannot be ruled out a priori, we
investigated nine drugs of this family for their ability to induce DNA repair
synthesis in primary cultures of rat and human hepatocytes. Each steroid was
tested in cultures from at least two male and two female donors of each species.
Hepatocytes were exposed for 20h to sub-toxic concentrations ranging from 1 to 50
micro M, and DNA repair induction was measured by quantitative autoradiography.
In primary rat hepatocytes, induction of DNA repair indicative of a frankly
positive response was detected in cultures from: 2/2 males and 3/3 females with
drospirenone, 2/2 males and 1/2 females with ethinylestradiol, 1/2 males and 1/2
females with oxymetholone, 1/2 males with norethisterone, 1/4 females with
progesterone, and 1/4 males with methyltestosterone. Consistent negative
responses were obtained with testosterone and stanozolol. A few inconclusive
responses were observed in rat hepatocytes exposed to progesterone,
medroxyprogesterone, norethisterone, methyltestosterone and oxymetholone. In
contrast, under the same experimental conditions the nine sex steroids provided
frankly negative responses in the large majority of cultures of primary
hepatocytes from both male and female human donors; the only exceptions being the
inconclusive responses obtained in cultures from two of the donors exposed to
norethisterone and to ethinylestradiol, and from one of the donors exposed to
testosterone, methyltestosterone, and stanozolol. These results and previous
findings concerning cyproterone and its structural analogues suggest that sex
steroids differ for their ability to induce DNA repair, and that their
genotoxicity may be: (i) different in rat and human hepatocytes, (ii) dependent
on the sex of the donor, and (iii) affected by inter-individual variability.

Hepatic effects of 17 alpha-alkylated anaboli-androgenic steroids.

. Tuesday, 8 July 2008
0 comments

HIV Hotline. 1998 Dec;8(5-6):2-5.

Hepatic effects of 17 alpha-alkylated anaboli-androgenic steroids.

[No authors listed]

AIDS: Use of 17 alpha-alkylated anabolic-androgenic steroids (17alpha-AAS) has
been connected to hepatotoxicity. These steroids are used clinically to treat
anemia, to prevent weight loss, and to treat wasting syndrome. The most common
types of 17alpha-AAS are Methyltestosterone, Oxandrolone, Oxymetholone and
Stanozolol. Liver disease and the effects of some anti-HIV drugs may contribute
to hepatic dysfunction. Signs of hepatic dysfunction are listed. For those
experiencing jaundice and related malfunctions, discontinuing the drug enables
patients to recover. In many cases those who did not exhibit jaundice may have
developed a tolerance for the drugs. Side effects such as cholestatic jaundice
only occurred in a small number of patients taking the recommended doses of
17alpha-AAS. Peliosis hepatitis, hepatic tumors, and hepatocellular adenomas are
other reported side effects. Proper dosing and monitoring of anabolic steroids
reduces the risk of hepatotoxicity.